23andMe

Anne Wojcicki convinced millions of people to spit in a tube and mail her their DNA. She turned 23andMe into a household name and a company once worth $6 billion. In 2025 it filed for bankruptcy, and she resigned, having watched the stock fall more than 95% from its peak.

23andMe is a case study in some of the hardest problems in business at once: a product people buy exactly once, a data set that turned from the company’s greatest asset into its greatest liability, and a founder who held so much control that no one could correct the course. After it collapsed, Wojcicki tried to buy the company she’d built back out of bankruptcy for about $42 million, a fraction of what it was once worth.

---

At a glance:

Founded	2006, by Anne Wojcicki (with Linda Avey and Paul Cusenza)
Product	At-home DNA testing for ancestry and health
Went public	2021, via SPAC, at a ~$3.5 billion valuation
Peak	~$6 billion market value
2023	Data breach exposed genetic data of ~7 million customers
March 2025	Files Chapter 11 bankruptcy; Wojcicki resigns as CEO
Stock decline	More than 95% from peak

---

The Story

Spit, and a mission to democratize DNA

Wojcicki co-founded 23andMe in 2006 with Linda Avey and Paul Cusenza, on a genuinely radical idea: let ordinary people access their own genetic information cheaply, without a doctor as gatekeeper. The product was simple and clever, a saliva kit you mailed back for a report on your ancestry and health traits. It made genetics personal, and it made 23andMe famous.

The peak: a $3.5 billion debut

For years, 23andMe rode a wave of curiosity, becoming a holiday-gift phenomenon and a cultural fixture. In 2021 it went public through a SPAC merger backed by Richard Branson, at a valuation around $3.5 billion, and its market value climbed toward $6 billion. On paper, a woman had built a multibillion-dollar consumer health company from a spit test.

The problem hiding in the product

Underneath the hype was a flaw that no amount of marketing could fix: you only need to learn your ancestry once. 23andMe sold a one-time product with almost no reason to buy again, which meant every year it had to find millions of brand-new customers just to stay flat. A business with no recurring revenue is running up a down escalator, and eventually demand for the kits dried up.

The breach and the collapse

Two things finished it. In 2023, a data breach exposed the genetic data of nearly 7 million customers, turning the company’s most valuable asset, its enormous DNA database, into a reputational and legal liability. And Wojcicki’s expensive bet on turning that data into a drug-development business burned cash without a payoff. The stock fell more than 95%, and in March 2025, 23andMe filed for Chapter 11 bankruptcy. Wojcicki resigned as CEO and moved to try to buy the company back for roughly $42 million.

The Strategy (and Why It Broke)

A product with no second purchase

The fatal flaw was structural. A DNA kit is a one-and-done purchase, so 23andMe could never build the repeat-customer base that makes consumer companies durable. It tried subscriptions and health features to create a reason to come back, but never solved the core problem. A business model without a reason to buy again has a ceiling built into it.

Data as the asset, and the liability

23andMe’s real ambition was never the kits, it was the database, one of the largest collections of consumer genetic data in the world, which it planned to monetize through drug research and partnerships. That data was the company’s crown jewel and, after the 2023 breach, its deepest wound. When your core asset is people’s most sensitive information, a single failure to protect it can be existential.

Founder control with no brakes

Wojcicki held roughly 49% of the voting power through super-voting shares, giving her near-total control of the company. When the board of seven independent directors disagreed with her direction, they resigned en masse in 2024 rather than being able to change course. Concentrated founder control can be a strength, but with no one able to check a founder’s worst bets, ownership structure becomes a risk of its own.

The Marketing

Making DNA testing a gift

At its height, 23andMe did the hard thing brilliantly: it made an abstract science into a mainstream consumer purchase and even a holiday gift. The promise of discovering your heritage was emotional and shareable, and it turned genetic testing into a cultural moment. The marketing worked, which is part of the lesson, because great marketing can sell a product whose business model still doesn’t work.

The Numbers

Year	Event
2006	23andMe founded
2021	Goes public via SPAC at ~$3.5B valuation; peaks near $6B
2023	Data breach exposes ~7 million customers’ genetic data
2024	All seven independent board directors resign
March 2025	Files Chapter 11 bankruptcy; Wojcicki resigns as CEO

From $6 billion to $42 million: The distance between 23andMe’s peak value and Wojcicki’s post-bankruptcy buyback offer is the whole story. A company can be a genuine innovation, a household name, and a public-market darling, and still collapse if the underlying business doesn’t have a reason for customers to come back.

What You Can Learn

Recurring revenue is everything. A product people buy once has a ceiling no amount of growth-hacking removes. Before you build, ask what makes a customer come back, because a business without repeat purchases is always refilling a bucket with a hole in it.

Your greatest asset can become your greatest liability. 23andMe’s DNA database was its whole future and, after a breach, its undoing. If your core asset is sensitive data, protecting it isn’t an IT line item, it’s survival.

Too much founder control removes the guardrails. Wojcicki’s super-voting shares meant no one could steer her away from bad bets. Some control protects a founder’s vision, but total control removes the checks that catch mistakes before they become fatal.

Hype is not a business. A splashy SPAC and a multibillion-dollar valuation didn’t fix a flawed model. Public-market enthusiasm can inflate a company far past what its fundamentals support, and the gap eventually closes.

Frequently Asked Questions

Who founded 23andMe?

Anne Wojcicki co-founded 23andMe in 2006 with Linda Avey and Paul Cusenza. Wojcicki served as CEO and became the company’s public face until resigning during its 2025 bankruptcy.

What happened to 23andMe?

After going public in 2021 at around a $3.5 billion valuation and peaking near $6 billion, 23andMe was hurt by weak repeat demand for its one-time DNA kits, a 2023 data breach affecting nearly 7 million customers, and heavy spending on drug development. It filed for Chapter 11 bankruptcy in March 2025.

Why did 23andMe fail?

The core issue was a product people buy only once, leaving no recurring revenue. That was compounded by a costly pivot into drug development, a major 2023 data breach that damaged trust, and a governance structure that gave founder Anne Wojcicki near-total control with few checks.

How much was 23andMe worth?

23andMe went public in 2021 at a valuation of roughly $3.5 billion and peaked at around $6 billion in market value. By its 2025 bankruptcy, its stock had fallen more than 95%, and Wojcicki moved to buy it back for about $42 million.

Sources

• Reuters, “DNA testing firm 23andMe files for bankruptcy,” March 2025. Bankruptcy, weak demand, and the 2023 breach.
• Fortune, “23andMe declares bankruptcy: Company timeline,” 2025. Timeline and Wojcicki’s resignation.
• Fortune, “23andMe was once worth $6 billion. Now CEO Anne Wojcicki wants to buy it back for $42 million,” 2025. Peak value, buyback attempt, founder-control critique.
• Inc., “The 23andMe Collapse Is a Master Class in Why Founders Shouldn’t Always Get Their Way”. The 95% stock drop, 6M+ breach, and board resignations.
• Yale Daily News, “23andMe founder Anne Wojcicki resigns as company files for bankruptcy,” March 2025. Resignation and co-founder detail.